Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials, supporting the development of precision oncology approaches.
The studies will focus on validating TROP2 as a biomarker, building on Genprex research showing that high TROP2 H-scores and low PTEN H-scores were associated with improved patient response and longer progression-free survival in NSCLC studies.
Roche Diagnostics will conduct assay validation using its TROP2 antibody, with Genprex aiming to complete the studies by the end of 2026 and integrate the findings into its NSCLC clinical programme.
The collaboration is intended to refine patient identification strategies for Genprex's Reqorsa Gene Therapy programme and advance biomarker-driven treatment approaches for cancer patients.
Coiled Therapeutics doses first patient with optimised AO-252 formulation
CREATE Medicines agrees strategic research collaboration with Australia's Monash University
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
Datroway approved in EU for first-line metastatic triple-negative breast cancer
Karyopharm reports topline Phase 3 trial results in endometrial cancer
Kaigene and Taisho enter exclusive KG006 licensing agreement in Japan
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
Octapharma to build USD1.5bn critical care manufacturing facility in Rock Hill, SC
Ractigen Therapeutics closes over USD31m financing for project advancement
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
European Commission approves RINVOQ for severe alopecia areata
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
Incyte's Opzelura approved in European Union for moderate atopic dermatitis